Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma.
4'Deoxydoxorubicin was evaluated in patients with advanced renal carcinoma. Only one partial remission was noted, and no significant cardiac toxicity was seen on serial evaluation of ejection fractions. Appropriate dose escalations were performed.
Kish
J A
JA
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201.
Ensley
J F
JF
al-Sarraf
M
M
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C030851:esorubicin